Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

References

• Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004;19:330–7
   Google Scholar
• Wasnich RD. Vertebral fracture epidemiology. Bone 1996;18(Suppl 3):179S–183S
   Google Scholar
• Bone health and osteoporosis: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services, Office of the Surgeon General; 2004
   Google Scholar
• Keen RW. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003;1:66–70
   PubMedGoogle Scholar
• Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391–401
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61
   PubMed Web of Science ®Google Scholar
• Eisman JA, Garcia-Hernandez PA, Ortiz-Luna G, et al. Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from DIVA [abstract P316SA]. Osteoporos Int 2006;17:S212
   PubMed Web of Science ®Google Scholar
• Hernandez CJ, Beaupre GS, Marcus R, Carter DR. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J Bone Miner Res 2002;17:1662–6
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Adachi R. Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 2007;66(Suppl II):681
   Google Scholar
• Recker R, Stakkestad JA, Chesnut 3rd CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890–9
   Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing IntraVenous Administration study. Arthritis Rheum 2006;54:1838–46
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–22
   PubMed Web of Science ®Google Scholar
• Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951–65
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [FIT Research Group]. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women [Hip Intervention Program Study Group]. New Engl J Med 2001;344:333–40
   PubMed Web of Science ®Google Scholar
• Marcus R, Wong M, Heath 3rd H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002;23: 16–37
   Google Scholar
• Delmas PD. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 2002;30:14–7
   PubMed Web of Science ®Google Scholar
• Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville: US Food and Drug Administration, Division of Metabolic and Endocrine Drug Products; 1994. Available at: http://www.fda.gov/cder/guidance/osteo.pdf [last accessed 3 July 2007]
   Google Scholar
• Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291–8
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517–23
   Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129–35
   PubMed Web of Science ®Google Scholar
• Liberman UA, Hochberg MC, Geusens P, et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int J Clin Pract 2006;60:1394–400
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508–16
   Google Scholar
• Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate. A meta-analysis [Alendronate Osteoporosis Treatment Study Group]. J Am Med Assoc 1997;277:1159–64
   PubMed Web of Science ®Google Scholar
• Civitelli R, Emkey R, Zaidi M, Lewiecki EM. Safety of intravenous ibandronate injections in postmenopausal osteoporosis: DIVA 2-year findings [abstract No. 199]. J Clin Densitom 2006;9:247
   Google Scholar
• Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract]. Arthritis Rheum 2005;52:4060
   Web of Science ®Google Scholar
• Adami S, Prince R, Halse J, et al. Two-year safety and tolerability profile of intravenous ibandronate injections: the DIVA study [abstract P258]. Osteoporos Int 2006; 17:S69
   Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371–87
   PubMed Web of Science ®Google Scholar
• Li Z, Meredith MP. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs meta-regression on group-level summary statistics. J Biopharm Stat 2003;13:777–92
   PubMedGoogle Scholar
• Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570–8
   Google Scholar
• Najib M, Aziz I. Yearly zoledronic acid in postmenopausal osteoporosis [comment on: New Engl J Med 2007;356:1809–22]. New Engl J Med 2007;357:713
   PubMed Web of Science ®Google Scholar
• Watts NB. Is it ethical to use placebos in osteoporosis clinical trials? Curr Osteoporos Rep 2004;2:31–6
   PubMedGoogle Scholar